Cargando…
Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is one common arrhythmia in the elderly. However, use of antithrombotic therapy in this population is not well known in the People’s Republic of China. This study aimed at investigating antithrombotic therapy status in elderly patients with NVAF in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354427/ https://www.ncbi.nlm.nih.gov/pubmed/25767378 http://dx.doi.org/10.2147/CIA.S67974 |
_version_ | 1782360762311770112 |
---|---|
author | Xiang, Wei Zhang, Jingwei Liu, Meilin Liu, Fang Feng, Xueru Wang, Yuchuan |
author_facet | Xiang, Wei Zhang, Jingwei Liu, Meilin Liu, Fang Feng, Xueru Wang, Yuchuan |
author_sort | Xiang, Wei |
collection | PubMed |
description | OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is one common arrhythmia in the elderly. However, use of antithrombotic therapy in this population is not well known in the People’s Republic of China. This study aimed at investigating antithrombotic therapy status in elderly patients with NVAF in our hospital. METHODS: A cross-sectional study of consecutive geriatric patients aged ≥60 years with NVAF who discharged from our hospital between January 2012 and December 2013 were collected. CHA(2)DS(2)-VASc score (cardiac failure or dysfunction, hypertension, age ≥75 [doubled], diabetes, stroke or transient ischemic attack [doubled], vascular disease, age 65–74, and sex category [female]) was used to analyze antithrombotic indication. RESULTS: We consecutively collected data of 1,000 discharged elderly patients (≥60 years) with NVAF (mean age 75.3±8.0 years, 75 years or older 54.7%, female 42.7%). The proportion of paroxysmal atrial fibrillation and non-paroxysmal atrial fibrillation (persistent or permanent) patients were 39.4% and 60.6%, respectively. Among 1,000 patients, 29.1% received oral anticoagulant therapy (OAT), including warfarin (27.8%) and novel oral anticoagulants (1.3%), 39.5% of patients received antiplatelet therapy, and 31.4% received neither therapy. Based on CHA(2)DS(2)-VASc score for stroke risk stratification, 68.9% patients with score ≥1 and 70.2% patients with score ≥2 received antithrombotic therapy, while the rates of OAT were 29.1% and 29.5%, respectively. Among patients with high stroke risk, those with paroxysmal atrial fibrillation were less likely to receive OAT compared with the patients with non-paroxysmal atrial fibrillation (19.5% vs 35.7%, P<0.001). The patients ≥75 years old had lower rate of OAT than the patients <75 years old (25.8% vs 34.8%, P=0.003). The patients with coronary artery disease had lower rate of OAT than the patients without coronary artery disease (24.4% vs 33.4%, P=0.003). Sex and history of stroke or transient ischemic attack had no effect on the use of OAT (30.8% vs 27.9%, P=0.326 and 28.8% vs 29.8%, P=0.761, respectively). CONCLUSION: OAT in elderly patients with NVAF in our hospital is underused, especially in those patients with higher risk of stroke. |
format | Online Article Text |
id | pubmed-4354427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43544272015-03-12 Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study Xiang, Wei Zhang, Jingwei Liu, Meilin Liu, Fang Feng, Xueru Wang, Yuchuan Clin Interv Aging Original Research OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is one common arrhythmia in the elderly. However, use of antithrombotic therapy in this population is not well known in the People’s Republic of China. This study aimed at investigating antithrombotic therapy status in elderly patients with NVAF in our hospital. METHODS: A cross-sectional study of consecutive geriatric patients aged ≥60 years with NVAF who discharged from our hospital between January 2012 and December 2013 were collected. CHA(2)DS(2)-VASc score (cardiac failure or dysfunction, hypertension, age ≥75 [doubled], diabetes, stroke or transient ischemic attack [doubled], vascular disease, age 65–74, and sex category [female]) was used to analyze antithrombotic indication. RESULTS: We consecutively collected data of 1,000 discharged elderly patients (≥60 years) with NVAF (mean age 75.3±8.0 years, 75 years or older 54.7%, female 42.7%). The proportion of paroxysmal atrial fibrillation and non-paroxysmal atrial fibrillation (persistent or permanent) patients were 39.4% and 60.6%, respectively. Among 1,000 patients, 29.1% received oral anticoagulant therapy (OAT), including warfarin (27.8%) and novel oral anticoagulants (1.3%), 39.5% of patients received antiplatelet therapy, and 31.4% received neither therapy. Based on CHA(2)DS(2)-VASc score for stroke risk stratification, 68.9% patients with score ≥1 and 70.2% patients with score ≥2 received antithrombotic therapy, while the rates of OAT were 29.1% and 29.5%, respectively. Among patients with high stroke risk, those with paroxysmal atrial fibrillation were less likely to receive OAT compared with the patients with non-paroxysmal atrial fibrillation (19.5% vs 35.7%, P<0.001). The patients ≥75 years old had lower rate of OAT than the patients <75 years old (25.8% vs 34.8%, P=0.003). The patients with coronary artery disease had lower rate of OAT than the patients without coronary artery disease (24.4% vs 33.4%, P=0.003). Sex and history of stroke or transient ischemic attack had no effect on the use of OAT (30.8% vs 27.9%, P=0.326 and 28.8% vs 29.8%, P=0.761, respectively). CONCLUSION: OAT in elderly patients with NVAF in our hospital is underused, especially in those patients with higher risk of stroke. Dove Medical Press 2015-03-02 /pmc/articles/PMC4354427/ /pubmed/25767378 http://dx.doi.org/10.2147/CIA.S67974 Text en © 2015 Xiang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Xiang, Wei Zhang, Jingwei Liu, Meilin Liu, Fang Feng, Xueru Wang, Yuchuan Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study |
title | Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study |
title_full | Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study |
title_fullStr | Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study |
title_full_unstemmed | Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study |
title_short | Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study |
title_sort | antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354427/ https://www.ncbi.nlm.nih.gov/pubmed/25767378 http://dx.doi.org/10.2147/CIA.S67974 |
work_keys_str_mv | AT xiangwei antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy AT zhangjingwei antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy AT liumeilin antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy AT liufang antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy AT fengxueru antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy AT wangyuchuan antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy |